Global beta rollout of NIQ’s Optiq Chat later this month will give more clients conversational access to explainable answers grounded in NIQ data and expertise



(BUSINESS WIRE)--NielsenIQ (NIQ), a leading consumer intelligence company, today announced that Optiq is now live within Discover, NIQ’s platform for accessing, analyzing and applying consumer and market intelligence, advancing the company’s strategy to make trusted consumer intelligence easier to access and apply.

Where Ask Arthur introduced new ways to explore and analyze NIQ data through AI within Discover, Optiq expands that experience across conversational AI, mobile access and enterprise AI integrations, giving clients greater flexibility to access and apply NIQ intelligence across the applications and workflows where they make decisions.

“AI models are becoming ubiquitous. Trusted intelligence is not,” said Irina Stoian, Chief AI Commercial Officer at NIQ. “That is why we are building the ... Read more »

Rapid expansion of AI computing, increasing electrification and rise of renewable energy are driving renewed interest in DC technology as part of future electrical systems
Both AC and DC systems have strategically important roles in meeting future electricity demand
Establishing common standards and developing DC-specific skills can help accelerate deployment


(BUSINESS WIRE)--ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with Boston Consulting Group (BCG). The report makes the case that direct current (DC) technology is moving from the periphery to the center of industrial, commercial, and digital infrastructure – and that the decisions made by business leaders and policymakers in the next two to three years will determine who shapes that transition and who inherits it.

The future of power distribution is not an either-or choice between alter ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. -
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms
Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies
Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1.

"People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily li ... Read more »

MUMBAI, India - Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes (BUSINESS WIRE) -- LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell ... Read more »

PARMA, Italy - HIGHLIGHTS H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic investment for treatment of hereditary angioedema (HAE) with acquisition of KalVista Pharmaceuticals EBITDA continues to remain close to 30%, reflecting continued strong profitability and disciplined resource allocation Recent Economic Footprint study highlights Chiesi's contribution to economic development, supporting 56,488 jobs globally, generating €6.0 billion in GDP impact and €2.0 billion in taxes and public revenues worldwide (BUSINESS WIRE) -- Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across the ... Read more »

WASHINGTON - Wednesday, 09. September 2026 AETOSWire Print Platform exceeds original $3 billion fundraising target, reflecting broad institutional demand for infrastructure credit (BUSINESS WIRE) -- EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the final close of EIG Senior Infrastructure Debt Fund VI (“SIDF VI”) at $1.9 billion, nearly double the size of its predecessor fund. Together with $2.1 billion committed to single investor vehicles, this exceeds the strategy's original $3 billion target and reflects strong demand from investors seeking customized and evergreen exposure to senior infrastructure debt. Since launching in July 2024, SIDF VI has already committed approximately $1 billion across 16 investments, reflecting strong proprietary origination capabilities. SIDF VI seeks to make directly originated, senior secured debt investments across a broad range of sectors, including power generation, renewable energy, e ... Read more »

TOKYO - Wednesday, 09. September 2026

- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach –

Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A.
Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A.
First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously.


(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), ... Read more »

Expansion provides access and expert ATA Carnet services for customers across new regions



(BUSINESS WIRE)--The Rock-It Company announced today the expansion of Dynamic Dox, the industry-leading provider of ATA Carnets, to now service partners and projects based in the United States, Canada and beyond.

Following over a decade of expertise and leading service across the United Kingdom since 2014, Dynamic Dox will now provide new regions with dedicated document preparation for time-sensitive logistics projects, and urgent ATA Carnets for international shipments and critical business travel needs. The news of the expansion follows Dynamic Dox’s recent brand refresh, introducing an updated identity and connection to The Rock-It Company as Dynamic Dox By Rock-It. The expansion is led by Amanda Barlow, VP of Global ATA Carnets at The Rock-It Company, who has helped to drive the platform’s growth in ATA Carnets, customs services and beyond.

The Rock-It Company ... Read more »

Appointments Support the Company's Ongoing Transformation Through Beauty Reimagined and Continued Focus on Consumer-Centric Growth

(BUSINESS WIRE) -- The Estée Lauder Companies Inc. (NYSE: EL) today announced expanded leadership roles for two members of its Executive Team. Brian Franz has been appointed Chief Technology & Transformation Officer, expanding his responsibilities to include leading the company's enterprise-wide transformation. Amber English has been named President, Digital & Online, The Americas and Global Amazon Lead, assuming new enterprise-wide responsibility for The Estée Lauder Companies’ global relationship with Amazon. Both will continue to report directly to Stéphane de La Faverie, President and Chief Executive Officer, and remain members of The Estée Lauder Companies’ Executive Team. Both appointments are effective immediately.

“Transformation at The Estée Lauder Companies is not a moment in time or a project with an end date. It’s a part ... Read more »

CUPERTINO, Calif. - Wednesday, 09. September 2026



AI-powered conversational agents help CSPs go beyond call and message blocking, disrupting fraudsters before they reach real customers.

(BUSINESS WIRE) -- Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and Apate.ai (“Apate”) have announced a partnership that equips communications service providers (CSPs) with advanced AI-powered fraud prevention capabilities designed to detect, disrupt, and investigate scam call operations.

According to the Global Anti-Scam Alliance, scammers stole an estimated $442 billion in 2025, with phone calls, text messages and emails being the top three communication channels used by scammers. Through the integration of Mobileum’s Active Intelligence Platform with Apate's conversational AI agents, CSPs can now move beyond traditional call blocking and take a more proactive role in disrupting scam activity.

Rather than simply preven ... Read more »